Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Carboplatin is in a class of medications known as platinum-cont

Trial Details

NCT ID

NCT07441681

Phase

PHASE3

Sponsor

NRG Oncology

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Biospecimen Collection
Carboplatin
Cetuximab
Computed Tomography
Intensity-Modulated Radiation Therapy
Magnetic Resonance Imaging

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Anaheim, California, United States|33.83529,-117.9145
Baldwin Park, California, United States|34.08529,-117.9609
Bellflower, California, United States|33.88168,-118.11701
Beverly Hills, California, United States|34.07362,-118.40036

Key Eligibility Criteria

Patients must have pathologically confirmed, previously untreated, unresected squamous cell carcinoma of the larynx, hypopharynx, oropharynx, or or…
Local evaluation of p16 status is required for all oropharynx patients prior to registration
Local evaluation of p16 status is recommended for non-oropharynx patients prior to registration
Locoregionally advanced head and neck squamous cell carcinoma (HNSCC) defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →